Related Experiment Videos
A rationally designed anticancer drug targeting a unique binding cavity of tubulin
F M Uckun1, C Mao, A O Vassilev
1Drug Discovery Program and Parker Hughes Cancer Center, Parker Hughes Institute, St. Paul, MN 55113, USA. fatih_uckun@mercury.ih.org
Bioorganic & Medicinal Chemistry Letters
|June 8, 2000
Abstract:
A novel mono-THF containing synthetic anticancer drug (WHI-261) was designed for targeting a previously unrecognized unique narrow binding cavity on the surface of tubulin. The anti-cancer activity of WHI-261 was confirmed using MTT assays. The structure-based design, synthesis, and biological activity of WHI-261 are reported.